I-Mab (IMAB) Prices 7.47M ADS IPO at $14/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
I-MAB Announces Pricing of U.S. Initial Public Offering
January 17, 2020 12:37 AM EST- ADSs to Begin Trading on Nasdaq on January 17, 2020 -
SHANGHAI, China and ROCKVILLE, Md., Jan. 17, 2020 (GLOBE NEWSWIRE) -- I-Mab (I-Mab or the Company) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced the pricing of its initial public offering of 7,407,400 American Depositary Shares (ADSs), each ten (10) ADSs representing twenty-three (23) ordinary shares of the Company, par value US$0.0001 per share, at US$14.00 per ADS, assuming the... More
